-
Je něco špatně v tomto záznamu ?
Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview
M. Bohonek, D. Kutac, JP. Acker, J. Seghatchian,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy
- MeSH
- krevní transfuze metody MeSH
- kryoprezervace metody MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
The essential historical knowledge and expertise developed over the past 5-6 decades on the safety / efficacy of conventional blood components therapy by blood transfusion establishments have guided the development of validated methods which have ensure optimal safety margins for frozen blood and its bioproducts with or even without pathogen reduction. Newer generations of pathogen reduced frozen red blood cell, plasma and platelet products and the standardised and safer pooling of human platelet lysate are now become available for potential clinical use. These types of whole blood-derived bioproducts not only reduce the risk of transmission of range of pathogenic blood-borne pathogen. As cryopreservation can be combined with PRT without significantly compromising in vitro quality characteristics or physiological capabilities, it allows us to maximize the available inventory of these blood products in both civil and military trauma settings. The main objective of this overview is to update readers and scientific / medical communities of the various building blocks needed to optimally grantee the pathogen safety of whole blood-derived bioproducts, with minimal untoward events to the recipients. While this is an emerging area, we are seeing the numerous potential opportunities that cryopreservation and pathogen inactivation can have on the transfused patient outcomes. This manuscript is informed by recent publications on this topic.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028344
- 003
- CZ-PrNML
- 005
- 20210114153559.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.transci.2020.102754 $2 doi
- 035 __
- $a (PubMed)32165117
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Bohonek, Milos $u Department of Haematology and Blood Transfusion, Military University Hospital Prague, Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic. Electronic address: Milos.Bohonek@uvn.cz.
- 245 10
- $a Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview / $c M. Bohonek, D. Kutac, JP. Acker, J. Seghatchian,
- 520 9_
- $a The essential historical knowledge and expertise developed over the past 5-6 decades on the safety / efficacy of conventional blood components therapy by blood transfusion establishments have guided the development of validated methods which have ensure optimal safety margins for frozen blood and its bioproducts with or even without pathogen reduction. Newer generations of pathogen reduced frozen red blood cell, plasma and platelet products and the standardised and safer pooling of human platelet lysate are now become available for potential clinical use. These types of whole blood-derived bioproducts not only reduce the risk of transmission of range of pathogenic blood-borne pathogen. As cryopreservation can be combined with PRT without significantly compromising in vitro quality characteristics or physiological capabilities, it allows us to maximize the available inventory of these blood products in both civil and military trauma settings. The main objective of this overview is to update readers and scientific / medical communities of the various building blocks needed to optimally grantee the pathogen safety of whole blood-derived bioproducts, with minimal untoward events to the recipients. While this is an emerging area, we are seeing the numerous potential opportunities that cryopreservation and pathogen inactivation can have on the transfused patient outcomes. This manuscript is informed by recent publications on this topic.
- 650 _2
- $a krevní transfuze $x metody $7 D001803
- 650 _2
- $a kryoprezervace $x metody $7 D015925
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kutac, Dominik $u Department of Haematology and Blood Transfusion, Military University Hospital Prague, Faculty of Military Health Sciences, University of Defence Hradec Kralove, Hradec Kralove, Czech Republic. Electronic address: dominik.kutac@uvn.cz.
- 700 1_
- $a Acker, Jason P $u Centre for Innovation, Canadian Blood Services, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada. Electronic address: jacker@ualberta.ca.
- 700 1_
- $a Seghatchian, Jerard $u International Consultancy in Blood Components Quality/Safety Improvement, Audit/Inspection, and DDR Strategies, London, England, UK. Electronic address: jseghatchian@btopenworld.com.
- 773 0_
- $w MED00008583 $t Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis $x 1473-0502 $g Roč. 59, č. 2 (2020), s. 102754
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32165117 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114153556 $b ABA008
- 999 __
- $a ok $b bmc $g 1608679 $s 1119524
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 59 $c 2 $d 102754 $e 20200228 $i 1473-0502 $m Transfusion and apheresis science $n Transfus Apher Sci $x MED00008583
- LZP __
- $a Pubmed-20210105
